ArticleJournal of internal medicine2026
Aspirin or non-steroidal anti-inflammatory drug initiation and subsequent bladder cancer evaluation.
Article in Journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWhether aspirin or non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) initiation may unmask unknown bladder cancers (BCs) by hematuria remains controversial.
objectivesTo evaluate unmasking, we compared cystoscopy rates, BC prevalence at cystoscopy, and invasive stage prevalence at diagnosis in aspirin or NSAID initiators with never-users.
methodsUsing the Danish population-based registries, we identified all new aspirin or NSAID users in 2005-2023 and a matched never-using comparison cohort. Second, we identified all first-time cystoscopy recipients in 2005-2022 with aspirin or NSAID initiation within 1 year prior or never-use in 10 years preceding cystoscopy. Comparing these groups, we computed hazard ratios of cystoscopy during 1-year follow-up, prevalence ratios of BC at cystoscopy, and invasive stage disease at diagnosis.
resultsAmong 50,771 aspirin initiators (median age: 67 years, 51% men) and 156,191 NSAID initiators (age: 45 years, 50% men) adjusted hazard ratios of cystoscopy were 1.54 (95% confidence interval [CI]: 1.38-1.72) and 1.56 (95% CI: 1.43-1.70) compared with never-users. Cystoscopy recipients included 683 aspirin (age: 70 years, 69% men) and 1414 NSAID initiators (age: 60 years, 63% men); standardized morbidity ratio weighted (SMRW) prevalence ratios were 0.97 (95% CI, 0.76-1.22) and 0.65 (95% CI, 0.51-0.82) compared with never-users. The SMRW invasive stage prevalence ratios were 0.81 (95% CI, 0.63-1.03) and 1.07 (95% CI, 0.85-1.34) in the aspirin and NSAID comparison.
conclusionThe combination of more cystoscopies and a lower prevalence of invasive stage at BC diagnosis may suggest the unmasking of asymptomatic BC in aspirin initiators. We did not find indications of unmasking with NSAID initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.